JPRN-UMIN000024042已完成2 期
A multicenter phase II trial of the efficacy and safety of tadalafil with pre-eclampsia. - Medication in Pre-Eclampsia Trial (MIE)II
Mie university hospital, Department of Obstetrics and Gynecology0 个研究点目标入组 160 人开始时间: 2016年9月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)uncontrolled hypertension 2)Delivery should be attempted because of severe preeclampsia 3) A result from antepartum fetal tests consisted of ultrasonography including Doppler imaging and fetal heart rate monitoring at eligibility indicates that delivery should be attempted. 4) A history of allergy to tadalafil 5) Concurrent medications that interact adversely with tadalafil 6) Relative contraindication of tadalafil treatment due to renal disease. 7) Relative contraindication of tadalafil treatment due to liver disease. 8) Relative contraindication of tadalafil treatment due to uncontrolled arrhythmia, hypertension (BP >170/110 mmHg), and hypotension (BP <80/40 mmHg). 9) Fetus with suspected chromosomal disorder and/or multiple congenital anomalies. 10) Relative contraindication of tadalafil treatment due to retinitis pigmentosa, coagulation defect, active gastric and/or intestinal ulcer, and venous obstructive disease. 11) Attending physician decides to entry inappropriate.
研究者
相似试验
已完成
2 期
A multicenter phase II trial of the efficacy and safety of tadalafil in fetus with early-onset growth restriction.Fetal growth restrictionJPRN-UMIN000023778Mie university hospital, Department of Obstetrics and Gynecology140
已完成
不适用
The efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary origin (CUP): prospective validation of diagnosis, classfication and metabolic responsesCarcinoma of unknown primary origin (CUP)CancerISRCTN17282276HS Greater Glasgow and Clyde (UK)59
进行中（未招募）
1 期
A clinical trial to evaluate the efficacy and safety ofpembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer. PANGEA-Breast”Patients with HER2-negative advanced breast cancer.MedDRA version: 19.0Level: LLTClassification code 10072737Term: Advanced breast cancerSystem Organ Class: 100000004864EUCTR2016-001779-54-ESGEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)36
已完成
2 期
Multi-Center Phase II Clinical Trial on Efficacy and Safety of Interferon Alfa-n1 + Sorafenib Combination Therapy in Renal Cell CarcinomaRenal cell carcinomaJPRN-UMIN000002466Japan RCC Trialist Collaborative Group (JRTCG)45
进行中（未招募）
不适用
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5qEUCTR2007-000450-31-SEThe Nordic MDS group50